Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Stockholders' Equity (Unaudited)

v3.7.0.1
Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)
$ in Thousands
Total
Common Stock
Paid-in Capital
Accumulated Other Comprehensive Income (loss)
Retained Deficit
Beginning Balance (in shares) at Dec. 31, 2015   108,322,250      
Beginning Balance at Dec. 31, 2015 $ 2,038,837 $ 1,082 $ 2,824,303 $ (55,177) $ (731,371)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net income (242,267)       (242,267)
Other Comprehensive Income 9,058     9,058  
Stock Compensation 3,341   3,341    
Issuance of Common Stock in public offerings, net of related expenses (in shares)   16,905,000      
Issuance of Common Stock in public offerings, net of related expenses 411,820 $ 169 411,651    
Issuance of Restricted Stock (in shares)   100,310      
Issuance of Restricted Stock 0 $ 1 (1)    
Ending Balance (in shares) at Mar. 31, 2016   125,327,560      
Ending Balance at Mar. 31, 2016 $ 2,220,789 $ 1,252 3,239,294 (46,119) (973,638)
Beginning Balance (in shares) at Dec. 31, 2016 158,829,816 158,829,816      
Beginning Balance at Dec. 31, 2016 $ 2,183,892 $ 1,588 3,946,442 (53,058) (1,711,080)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net income 154,455       154,455
Other Comprehensive Income 1,373     1,373  
Stock Compensation 2,553   2,553    
Issuance of Common Stock for the Vitruvian Acquisition, net of related expenses (in shares)   23,852,117      
Issuance of Common Stock for the Vitruvian Acquisition, net of related expenses 459,481 $ 239 459,242    
Issuance of Restricted Stock (in shares)   153,868      
Issuance of Restricted Stock $ 0 $ 1 (1)    
Ending Balance (in shares) at Mar. 31, 2017 182,835,801 182,835,801      
Ending Balance at Mar. 31, 2017 $ 2,801,754 $ 1,828 $ 4,408,236 $ (51,685) $ (1,556,625)